Equity, Access and Economic Evaluation in Rare Diseases: The Impact of Orphan Drug Legislation on Health Policy and Patient Care

Author： Bosanquet N.  

Publisher： Adis International

ISSN： 1175-9046

Source： Pharmaceutical Development and Regulation, Vol.1, Iss.3, 2003-01, pp. : 151-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orphan Drugs for Rare Diseases: Is it Time to Revisit Their Special Market Access Status?

By Simoens Steven  

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1437-1443

Adis International

Access to resources Recommend Favorite

Measuring the Patient Health, Societal and Economic Benefits of US Pediatric Therapeutics Legislation

By Vernon John A.   Shortenhaus Scott H.  

Pediatric Drugs, Vol. 14, Iss. 5, 2012-10 ,pp. : 283-294

Adis International

Access to resources Recommend Favorite

Impact of patient navigation in eliminating economic disparities in cancer care

By  

Cancer, Vol. 121, Iss. 22, 2015-11 ,pp. : 4025-4034

Blackwell Publishing

Access to resources Recommend Favorite

Reconciliation of Economic Concerns and Health Policy: Illustration of an Equity Adjustment Procedure Using Proportional Shortfall

By Elly A. Stolk  

PharmacoEconomics, Vol. 22, Iss. 17, 2004-01 ,pp. : 1097-1107

Adis International

Access to resources Recommend Favorite

The longitudinal impact of patient navigation on equity in colorectal cancer screening in a large primary care network

By Percac-Lima Sanja   López Lenny   Ashburner Jeffrey M.   Green Alexander R.   Atlas Steven J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 2025-2031

Blackwell Publishing

Access to resources Recommend Favorite